The 96 amino acid viral protein R (Vpr) of human immunodeficiency virus type 1 (HIV-1) was detected during virus assembly in intracellular vacuoles and at the plasma membrane on peripheral blood mononuclear cells. In both immature and mature virus particles, Vpr was located immediately beneath the viral envelope, colocalizing with the core structural protein, Gag p24. Vpr was present in intracellular HIV-1 wild-type virions at 50 % of the level found in extracellular HIV-1 particles. Cells infected with HIV-1 strains with C-terminal truncations of Vpr manifested a different pattern of Vpr expression. A mutant with an alteration of amino acids 79 to 85 exhibited a 23 % reduction in total levels of Vpr expression, but a marked accumulation of Vpr in intracellular rather than extracellular virions. A mutant with the last 17 amino acids of Vpr deleted expressed only 10 % of wild-type levels of Vpr. These observations indicate that Vpr is incorporated into virions from the cytoplasmic aspect of either the vacuolar or plasma membrane. Furthermore, the proportion of Vpr on intracellular compared to extracellular virions is affected by a specific locus within the protein.
Introduction
Human immunodeficiency virus (HIV) is released from the host cell surface by budding from the plasma membrane (Gelderblom, 1991) . The budding process releases immature virus particles containing a noncondensed core of Gag precursor proteins, together with the RNA genome and viral enzymes necessary for initiation of replication, all enclosed within a lipid bilayer containing the envelope proteins. Maturation of the virus particle, associated with viral protease activity, results in condensation of the particle core.
Viral protein R (Vpr) is incorporated into the virion. This involves an association of Vpr with the C terminus of the Gag precursor protein, Pr55 gag (Cohen et al., 1990b; Yuan et aI., 1990; Lu et al., 1993; Paxton et aI., 1993) . Vpr is one of seven regulatory proteins expressed by all HIV types and simian immunodeficiency virus (Rosen, 1991) . It encodes a 96 amino acid protein that is dispensable for virus replication in T lymphoid cell lines (Dedera et al., 1989) . However, Vpr accelerates HIV-1 replication about threefold in a variety of T lymphoid cell lines, and to a significantly greater degree in primary macrophages (Ogawa et aI., 1989; Hattori et aI., 1990; Westervelt et al., 1992) . Vpr has also been shown to increase gene expression non-specifically by threefold from a wide range of transcriptional promoters, by a mechanism that remains to be defined (Cohen et al., 1990a) . The packaging of Vpr into the virions suggests that this protein plays an important role in virus assembly or infectivity (Cohen et al., 1990a; Yuan et al., 1990) .
The subcellular localization of Vpr in infected cells has been determined by subcellular fractionation and indirect immunofluorescence microscopy (Lu et al., 1993) . These data suggest that Vpr expression in the absence of other viral proteins results in a predominant localization in the nucleus. However, coexpression of Gag Pr5 5 gag results in the release of a portion of the expressed Vpr protein in extracellular virions. In the present study, we defined more carefully the localization of Vpr during virus assembly at both intracellular and extracellular sites using wild-type and mutants forms of Vpr with a double immunogold electron microscopic labelling technique.
Methods
Cell lines and culture. COS-7 cells were obtained from the ATCC and maintained in Dulbecco's modified Eagle's medium supplemented with heat-inactivated fetal calf serum, 1 mM-pyruvate, 100 units/ml penicillin and 100 gg/ml streptomycin. Peripheral blood mononuclear cells (PBMCs) were purified from normal human leukocytes by centrifugation onto Ficoll. After 3 days of stimulation with phytohaemagglutinin (15 lag/ml; Sigma), PBMCs were maintained in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum, 4mMglutamine, recombinant interleukin 2 (50 units/ml; Cetus), 100 units/ml penicillin and 100 lag/ml streptomycin. Wang, Y.-L. Lu and L. Ratner Vpr mutants. HIV-I mutant SRIG was made from a proviral done, NLHXADA(GG), which expresses a 96 amino acid form of Vpr (Westervelt et al., 1992) . In this mutant four amino acids of Vpr (residues 79 to 82, numbered according to Myers et al., 1992) , Ser-Arg-Ile-Gly, were deleted and the Arg at position 85 was changed to Gln. The mutant was made by inserting the sequence 5' TCGACATGTTA-CTCAACAGAGGAGAGCAAGAAACGGAGCCAGTAGATCT-TAG3'into the Sall site at nucleotide 5785 by linker ligation.
The mutant CRST, in which residues 80 to 96 of Vpr were deleted, was constructed by digestion of NLHXADA(GG) with Sall and bluntending with the Klenow fragment of Escherichia coli DNA polymerase 1. The C-terminal amino acid sequence of wild-type Vpr and the mutants, SRIG and CRST, are shown below (the substituted amino acids are shown underlined): together with 2 lag of pCV1, a tat expression vector (Arya et al., 1985) .
The calcium phosphate precipitation method was used for transfection, and 5 hours later the cells were treated with 10% DMSO for 2 min before being washed twice with PBS. Cell culture supernatants were harvested after 48 h and filtered (0-2 lam Millipore filter). Culture supernatant (5 ml) was used to infect 1 x 107 PBMCs. The cells were collected as pellets 7 days post-infection. After washing with serum-free culture medium, the cells were fixed in freshly prepared 2.5% glutaraldehyde in PBS for 30 rain at room temperature. After fixation, the cells were washed in PBS overnight, dehydrated in graded concentrations of ethanol and then embedded in LR white acrylic resin (Stransky & Gay, 1991) .
Post-embedding immunoelectron microscopy. Sections of resin containing the cells, with a thickness of 100 nm, were collected on 270mesh nickel or gold grids for immunocytochemical analysis Gelderblom, 1991) . The sections were etched with freshly prepared 5 % H202 for 5 to 10 min in a vacuum chamber. Non-specific binding was blocked with 1% BSA. Ypr rabbit antiserum was prepared as previously described (Lu et al., 1993) . The mouse monoclonal antibody C246, which reacts to Gag p24, was kindly provided by T.-W. Chang. The sheep antibody to Env gpl20 was obtained from BioCell. For dual labelling, the anti-Vpr antiserum was added first and incubated at 20 °C for 1 h, followed by a wash with PBS, and then the mouse anti-Gag p24 or sheep anti-Env gp120 was applied. The cells were then washed in Tris-buffered saline (TBS) and 15 nm gold particle-conjugated goat anti-rabbit IgG (Auroprobe EM; Amersham) and either 5 nm gold particle-conjugated goat anti-mouse IgG (Amersham) or 10 nm gold particle-conjugated donkey anti-sheep IgG (BioCell) were added. Sections were stained with uranyl acetate and lead citrate and examined under a Zeiss electron microscope.
Results

Expression o f wild-type and mutant Vpr proteins
HIV-1 strains capable of encoding a full-length Vpr protein, or m u t a t e d forms of Vpr with deletions were used in this study. To confirm that the m u t a t i o n s gave rise to proteins of the predicted Mr and with similar stability a n d a n t i b o d y reactivity, the wild-type a n d m u t a t e d ( C R S T a n d S R I G ) vpr genes were cloned into a r e c o m b i n a n t vaccinia virus expression system. After expression in BSC-40 cells, the specific Vpr proteins were i m m u n o p r e c i p i t a t e d with a rabbit anti-Vpr antiserum a n d analysed by P A G E (Fig. 1) . The electrophoretic mobility of wild-type Vpr was consistent with a protein of 11.4K, slightly larger t h a n that predicted for a 96 a m i n o acid protein, b u t consistent with other studies of Vpr (Lu et al., 1993 ; P a x t o n et al., 1993). M u t a n t Vpr protein from S R I G has a deletion of four a m i n o acids and an electrophoretic mobility that was consistent with a decrease of I K in Mr, compared to the wild-type. M u t a n t Vpr protein from C R S T has a deletion of 17 a m i n o acids, and an electrophoretic mobility consistent with a decrease of 3K. All three vpr gene products reacted with the rabbit polyclonal anti-Vpr antiserum.
Vpr expression in intracellular and extracellular virions
HIV-1 infection of primary P B M C s was examined by i m m u n o g o l d electron microscopy. Virus particles were f o u n d b u d d i n g at the plasma m e m b r a n e ( Fig. 2a ) a n d within intracellular vacuoles ( Fig. 2a, b) . Budding virus particles at intracellular m e m b r a n e s were also Fig. 3 . Schematic representation of possible locations of Vpr-specific gold particles in HIV-1 virions embedded in thin resin sections. HIV-1 virions associated with infected cells were embedded in resin and cut into sections of 100 nm in thickness for post-embedding immunostaining and electron microscopic observations. Virions located at the upper (a) or lower portion of the section (f) would have been cut tangentially and the exposed Vpr antigen could be labelled with the antibody if Vpr was situated near or beneath the viral envelope. These virions would be predicted to appear smaller under the electron microscope and the gold particles would form a cluster. Virions cut through the centre would be predicted to appear larger and gold particles would form a ring-shaped pattern with (b) or without a core (d and e). The diameter of these virions would appear to be similar to that of typical virions. Virions embedded within the resin would not be accessible to H202 etching and their associated antigens would not be exposed. A typical virion diameter is approximately 100 nm.
immunogold-labelled with the anti-Vpr antiserum (Fig.  2 a) . Particles at both sites were Vpr-positive, as indicated by indirect immunolabelling with gold particles. N o significant background labelling was seen in the absence of HIV-1, or when the Vpr antiserum was omitted or substituted with a Vpx antiserum (data not shown). The diameter of the virions was about 100 nm. With 100 nm-thick sections, the virus particles may be cut at different levels, as shown schematically in Fig. 3 . Sections through the mid-portion of the virion would be predicted to show immunogold labelling in a ring-like pattern if Vpr was situated primarily just beneath the viral envelope ( Fig. 3 b, e ). With sections near the edge of a virion (Fig.  3 a, f ) , immunogold labelling of protein just beneath the viral envelope would be predicted to cause clusters of gold particles. Several examples of such gold particle distributions are evident in Fig. 2(c) .
Vpr expression during virus budding
Vpr gold labelling was also identified on virus particles budding from the plasma m e m b r a n e (Fig. 4) . I m m u n olabelled Vpr could be identified on the condensed m e m b r a n e areas of budding (Fig. 4a, b ) and beneath the virus envelope of immature virus particles ( Fig. 4 b to f ) . In some cases, a ring-shaped distribution of gold-labelled Vpr was evident (Fig. 4d, f) . In dual labelling experiments, gold particles (15 nm) specific for Vpr were found beneath the virus envelope, whereas G a g p24-specific gold particles (5 nm) were generally seen in the core of the virion (Fig. 4d to f ) .
Wild-type and mutant Vpr expression in virions
Virions containing the 96 amino acid wild-type Vpr protein as well as deletion mutants with alterations between amino acids 79 and 85 (SRIG) or a truncation mutant missing the C-terminal 17 amino acids (CRST) were also examined. S R I G virions (Fig. 5b) contained Vpr-specific gold particles in a similar distribution to that of wild-type virions (Fig. 5a ). However, C R S T virions contained very few Vpr-specific gold particles (Fig. 5c ).
Quantification of Vpr-specific gold particles was performed on several hundred electron micrographs and the number of intracellular and extracellular particles per virion determined (Table 1, Fig. 6 ). Wild-type virions were labelled with an average of 1.5 Vpr-specific gold particles per virion, whereas S R I G virions had an average of 1.1 particles per virion and C R S T virions contained only 0" 1 particles per virion. Since both Vpr mutants are Vpr mutant SRIG virions also labelled with Vpr-specific gold particles (15 nm, arrow 1). Gag p24-specific gold particles (5 nm, arrow 2) and Env gpl20-specific gold particles (10 nm, arrow 3) were also identified. An average of 1.1 Vpr-specific gold particles per virion was measured. The bar represents 200 nm. (c) Vpr mutant CRST virions showed very little Vpr-specific labelling (arrow 1), whereas Gag p24-specific gold particles were still observed (5 nm, arrow 2). An average of 0.1 Vprspecific gold particles per virion was counted. The bar represents 200 nm.
recognized by the Vpr-antiserum ( Fig. 1 ; J. J. Wang et al., unpublished results), the lower number of Vprspecific gold particles on CRST virions must be due to lower expression of the mutant protein in the virion, rather than a loss of immunogenicity.
With the wild-type, intracellular virions contained about half the number of Vpr-specific gold particles per virion compared to extracellular virions (Table 1, Fig. 6 ). In contrast, SRIG intracellular virions were immunolabelled to a greater extent with the Vpr antiserum than SRIG extracellular virions. The primary difference in SRIG virions compared to wild-type virions is a result of the much lower level of Vpr-specific gold particles in extracellular virions (0-4 for SRIG compared to 1-6 for wild-type), whereas no significant differences were seen in the number of these particles in intracellular virions (0.9 for SRIG and 0"8 for wild-type).
Discussion
The current findings demonstrate that HIV-I virions assemble in infected PBMCs by budding into cytoplasmic vacuoles and by budding from the plasma membrane. Other investigators have also noted HIV-1 virions budding into cytoplasmic vacuoles of infected primary monocytes (Orenstein et al., 1988) , the U937 monocytoid cell line (Pautrat et al., 1990) and the JM T lymphoid cell line (Grief et al., 1991 ). Orenstein et al. (1988 and Grief et al. (1991) identified these cytoplasmic vacuoles as Golgi saccules. Our observations of HIV-l-infected PBMCs failed to identify virions associated with typical Golgi apparatus. However, it is possible that the IP: 54.70.40.11
On: Thu, 13 Dec 2018 08:49:10 cytoplasmic vacuoles associated with HIV-1 virions in PBMCs are derived from the endoplasmic reticulum or Golgi saccules. Dual-labelling immunogold electron microscopy experiments should be useful in further characterizing the cellular compartment involved.
The Vpr protein was detected by immunogold electron microscopy at sites of virus budding, intracellularly as well as at the plasma membrane, in both immature and mature virions. Our triple immunolabelling studies demonstrated the localization of Vpr, Gag p24 and Env gpl20 proteins in virions. Lower levels of Gag immunolabelling than Vpr are a consequence of the use of a monoclonal antibody for Gag p24, whose epitope is more easily lost during fixation than the multiple epitopes recognized by the anti-Vpr antiserum. The low intensity of gp 120 labelling in this study is consistent with previous studies and reflects a lower level of gpl20 than p24 incorporation into virions Hart et aL, •993) . In virions, Vpr was generally localized beneath the viral envelope. This is consistent with biochemical data suggesting that Vpr packaging into virions is mediated by an interaction with the C-terminal portion of the Gag precursor protein, which is cleaved into the p6 protein (Lu et al., 1993 ; Paxton et al., 1993) . Though the function of the Gag p6 protein is unclear, it has been proposed to make up a core-envelope linker, situated just beneath the virus envelope .
Mutations in vpr had relatively minor effects on virus replication in PBMCs (Dedera et al., 1989; Ogawa et al., 1989; J. J. Wang et al., unpublished results) . However, virions derived from a HIV-1 strain in which the Cterminal 17 amino acids of Vpr were deleted (CRST) exhibited markedly decreased levels of virion-associated Vpr. This finding is attributed to a reduction in Vpr packaging into virus particles, but additional defects in Vpr transport or stability cannot be excluded.
A mutant Vpr protein (SRIG), in which residues 79 to 85 were altered, was packaged normally into virions at intracellular sites, but was partially defective in incorporation into virions budding at the plasma membrane. Whereas the ratio of full-length Vpr incorporation into extracellular versus intracellular virions was approximately 1.6, the ratio for the SRIG mutant Vpr was 0.4. These results indicate that the altered sequences may be important for intracellular targeting of Vpr.
Our recent data indicated that when Vpr was expressed in the absence of other viral proteins, it was found primarily in the nucleus (Lu et al., 1993) . However, when Vpr was coexpressed with the HIV-1 Gag precursor protein, it was incorporated into virions. These findings provide further evidence that other viral proteins are critical for export of Vpr from infected ceils.
In conclusion, our results show that Vpr is localized in virions primarily beneath the viral envelope. Furthermore, Vpr is incorporated into HIV-1 virions on cellular vacuolar membranes as well as at the plasma membrane. An alteration of the highly conserved sequence at residues 79 to 85 results in redistribution of Vpr virion incorporation to favour intracellular rather than extracellular budding virions. Additional studies of the interaction of Vpr with the viral core structure will be necessary to decipher its contribution to HIV-1 replication.
